A Phase 1 Study of BMS-986393 CAR T Cell Therapy in People With Multiple Myeloma


Full Title

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component


Researchers want to find the best dose of BMS-986393 to use with other drugs to treat multiple myeloma. The people in this study have multiple myeloma that keeps growing or came back after treatment.

BMS-986393 is a form of chimeric antigen receptor (CAR) T cell therapy, a type of cellular immunotherapy. With CAR T cell therapy, white blood cells called T cells are removed from your body. The T cells are altered in a lab to recognize proteins on your cancer cells. They are then multiplied to larger numbers and returned to your body to find and destroy cancer cells. BMS-986393 is given intravenously (by vein).

Doctors believe that giving BMS-986393 with other medications will be more effective against multiple myeloma than BMS-986393 alone. If you join this study, you will get BMS-986393 plus one of these treatments:

  • Alnuctamab, which boosts the body’s natural defenses to fight cancer. It is given by injection under the skin.
  • Mezigdomide, which attaches to a protein called cereblon to help cause cancer cells to die. It is taken orally (by mouth).
  • Iberdomide, which also attaches to cereblon and is taken orally.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have multiple myeloma that came back or keeps growing even after treatment.
  • Have recovered from the serious side effects of prior therapies before getting the study treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Sham Mailankody’s office at 646-608-2091.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID